Navigation Links
Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association

the placebo arm. The hazard ratio was 0.64 (95% CI: 0.51-0.79, p<0.001), which translates into a 36% reduction in the relative risk of pain progression. These results were consistent across multiple pre-defined subsets of patients, including patients treated with prior Taxotere(R) (docetaxel). All pain progression events were assigned by a blinded independent review committee. Complementing the time to pain progression data, pain response rates were 24.2 percent for the satraplatin plus prednisone arm (N=351) compared with 13.8 percent for the placebo arm (N=181) (p=0.005). Pain response rates for patients treated with prior Taxotere were 25.7 percent for the satraplatin arm compared with 13.1 percent for control (p<0.015). All of the findings presented today continue to build on the data previously presented from the SPARC trial.

Pain response was assessed by patients using a weekly present pain intensity (PPI) and analgesic score. The PPI score was defined according to the McGill-Melzack questionnaire with 0 = no pain, 1 = mild pain, 2 = discomforting pain, 3 = distressing pain, 4 = horrible pain and 5 = excruciating pain. The criteria for pain response are a greater than or equal to 2 point reduction in the patients' weekly PPI score from baseline and maintenance of the two point reduction for at least five consecutive weeks in the setting of a stable or decreasing weekly analgesic score compared to baseline. Patients were evaluable for pain response if their baseline PPI score was greater than or equal to one and had completed four consecutive weekly assessments of PPI and analgesic scores during the study treatment.

Safety findings in the SPARC trial were consistent with previous clinical studies involving satraplatin. The most common adverse reactions consisted of myelosuppression (bone marrow functions): Twenty-one percent of patients in the satraplatin arm experienced grade 3 or 4 thrombocytopenia; 14 percent had leucopenia and 21 percent had n
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:9/30/2014)... Inc. ( www.synapsebiomedical.com ) announced today it has ... its NeuRx DPS® System for ALS patients.  The ... requirement was implanted over a month and a ... is the only medical device approved by the ... device that obtained approval at the end of ...
(Date:9/30/2014)... Netherlands , Sept. 30, 2014  eHealth, ... phone storage and access of this information, has ... Slot , however, that has not translated into ... http://photos.prnewswire.com/prnh/20140929/149122 Photo - http://photos.prnewswire.com/prnh/20140929/149123 ... the past few years developing MWD® Health Manager ...
(Date:9/30/2014)... 30, 2014 It is evident from the industry ... not performing upto expectations due to the lack of promotional ... the intake of omega-3 fatty acids. Among omega-3 ingredient sources ... oil, attributed to the large vegetarian population in ... fatty acid (PUFAs) ingredients is in growth stage of its ...
Breaking Medicine Technology:Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 3MWD Challenges the Big eHealth Players With New Software for Your Smartphone 2Omega-3 Polyunsaturated Fatty Acids (PUFAs) - An Indian Market Overview 2
... FRANCISCO, Oct. 29 Medivation, Inc. (Nasdaq: MDVN ... webcast with management to discuss third quarter 2010 financial results ... at 4:30 p.m. Eastern Time. A press release for the ... markets close on November 5, 2010. Interested ...
... N.Y., Oct. 29 Henry Schein, Inc. (Nasdaq: ... to office-based practitioners, today reported record financial results for the ... the third quarter of 2010 were $1.9 billion, an increase ... consists of 16.4% growth in local currencies and a decline ...
Cached Medicine Technology:Henry Schein Reports Record Third Quarter Results 2Henry Schein Reports Record Third Quarter Results 3Henry Schein Reports Record Third Quarter Results 4Henry Schein Reports Record Third Quarter Results 5Henry Schein Reports Record Third Quarter Results 6Henry Schein Reports Record Third Quarter Results 7Henry Schein Reports Record Third Quarter Results 8Henry Schein Reports Record Third Quarter Results 9Henry Schein Reports Record Third Quarter Results 10Henry Schein Reports Record Third Quarter Results 11
(Date:9/30/2014)... Visit Pam and Steve’s quiet home in the ... a loving couple facing the most monumental challenge of ... Steve was diagnosed with ALS – more commonly known ... the couple’s second wedding anniversary. Pam is now ... “Care, Support & ALS,” that’s part of the ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 A highlight ... Optics (AMO) at the American Academy of Ophthalmology meeting ... LASIK surgeon Jeffrey Martin, MD on the ... is the Managing Partner of North Shore Eye Care ... SUNY Stony Brook. , This year’s 118th Annual American ...
(Date:9/30/2014)... News) -- Herceptin is the best drug treatment for ... remain the standard of care for that type of ... trial. HER2-positive breast cancers tend to be more ... the Mayo Clinic. For the study, more than ... or Tykerb (lapatinib) in addition to standard chemotherapy. ...
(Date:9/30/2014)... September 30, 2014 The St. Louis ... SLUCare Physician Group, comprised of more than 500 physicians, ... number of initiatives. With the recent addition of ... strengthening its market footprint to better respond to the ... , SLPA is a physician-led clinically integrated network (CIN) ...
(Date:9/30/2014)... Francisco, California (PRWEB) September 30, 2014 ... expected to reach USD 8,020.1 million by 2020, ... Research, Inc. Growing demand for personalized medicine and ... diagnostic technologies are expected to be key factors ... Moreover, the growing global base of geriatric population ...
Breaking Medicine News(10 mins):Health News:Hospice Provides Care and Support to Patients and Family Caregivers with ALS 2Health News:Global Laser Technology Leader Selects Jeffrey Martin, MD To Address Colleagues During International Symposium In Chicago 2014 2Health News:Global Laser Technology Leader Selects Jeffrey Martin, MD To Address Colleagues During International Symposium In Chicago 2014 3Health News:St. Louis Physician Alliance Expands Network and Market Footprint with Recent Addition of SLUCare Physician Group 2Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 2Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 3Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 4Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 5Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 6
... has invited best-selling author and noted physician Abraham Verghese to ... and Human Values at 7:30 p.m., Monday, Oct. 24 at ... Indian-American immigrant to the United States, Dr. Verghese,s varied professional ... India studies program at UH," said Lois Zamora, chair of ...
... Phase III trial of RTS,S*, published online today in the ... malaria vaccine candidate to provide young African children with significant ... and tolerability profile. The results were announced today at the ... in Seattle, Washington. Half the world,s population is at ...
... HealthDay Reporter , MONDAY, Oct. 17 (HealthDay ... conventional Pap tests as a cervical cancer screening tool ... The U.S. Preventive Services Task Force ... researchers are now seeking to fine-tune these guidelines. The ...
... (IAN Project) launches a national survey to study the ... (ASD). Bullying, a pervasive problem among youth, has attracted ... lasting, and sometimes tragic, effects on children and teenagers ... be especially vulnerable targets due to their social deficits ...
... (HealthDay News) -- Experts at the American Academy of Pediatrics ... for sudden infant death syndrome (SIDS). Those are two ... SIDS guidelines. Since 1992, when the AAP recommended that ... SIDS has declined sharply in the United States, according to ...
... Cypress, CA, October 18, 2011 Technology has radically ... this more evident than in the field of gynecologic ... teaching minimally invasive treatment for women,s health problems, will ... tools among the hundreds of postgraduate courses and practice ...
Cached Medicine News:Health News:Dr. Abraham Verghese to give John P. McGovern Lecture on Oct. 24 2Health News:Malaria vaccine candidate, RTS,S reduces the risk of malaria by half in African children 2Health News:Malaria vaccine candidate, RTS,S reduces the risk of malaria by half in African children 3Health News:Pap Test Still Best for Cervical Cancer Screening, Experts Say 2Health News:Pap Test Still Best for Cervical Cancer Screening, Experts Say 3Health News:National survey will measure how bullying impacts children with autism 2Health News:Breast-Feeding, Vaccinations Lower SIDS Risk, Experts Say 2Health News:Innovations in minimally invasive surgery and education are highlights of 40th AAGL Global Congress 2Health News:Innovations in minimally invasive surgery and education are highlights of 40th AAGL Global Congress 3Health News:Innovations in minimally invasive surgery and education are highlights of 40th AAGL Global Congress 4
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medicine Products: